Stock Analysis
- United States
- /
- Electronic Equipment and Components
- /
- NasdaqGM:MASS
908 Devices Full Year 2022 Earnings: EPS Misses Expectations
908 Devices (NASDAQ:MASS) Full Year 2022 Results
Key Financial Results
- Revenue: US$46.9m (up 11% from FY 2021).
- Net loss: US$33.6m (loss widened by 51% from FY 2021).
- US$1.07 loss per share (further deteriorated from US$0.79 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
908 Devices EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.5%.
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Electronic industry in the US.
Performance of the American Electronic industry.
The company's shares are up 7.6% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 3 warning signs for 908 Devices you should know about.
What are the risks and opportunities for 908 Devices?
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.
Rewards
Revenue is forecast to grow 17.97% per year
Risks
Shareholders have been diluted in the past year
Volatile share price over the past 3 months
Currently unprofitable and not forecast to become profitable over the next 3 years
Further research on
908 Devices
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:MASS
908 Devices
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.
Excellent balance sheet and overvalued.
